Xue, Zhichao
Lui, Vivian Wai Yan
Li, Yongshu
Jia, Lin
You, Chanping
Li, Xin
Piao, Wenying
Yuan, Hui
Khong, Pek Lan
Lo, Kwok Wai
Cheung, Lydia Wai Ting
Lee, Victor Ho Fan
Lee, Anne Wing Mui
Tsao, Sai Wah
Tsang, Chi Man
Funding for this research was provided by:
Health and Medical Research Fund (04151726)
General Research Fund (1191556, 17111516)
Health and Medical Research Fund (05162386)
Collaborative Research Fund (C7027-16G, C1013-15G, C4001-18GF)
NSFC/RGC Joint Research Project (N_HKU735/18, 81861168033)
General Research Fund (17121616, 14168517)
Research Impact Fund (R4015-19F, R4017-18)
Health and Medical Research Fund (15160691)
Innovation and Technology Fund (UIM/329)
National Institutes of Health (1R01CA229836-01A)
Article History
Received: 22 June 2020
Accepted: 4 November 2020
First Online: 26 November 2020
Ethics approval and consent to participate
: All animal experiments were conducted under conditions compliant with the animal license issued by the Hong Kong Department of Health and with the approval of the Committee on the Use of Live Animals in Teaching and Research (CULATR) of the University of Hong Kong (CULATR No. 3477).
: All authors involved in the study provided their consent to the submission of this article for publication.
: The authors declare that they have no competing interests for this study. For funding unrelated to this study, VWYL receives funding from the Hong Kong Cancer Fund, Hong Kong SAR on an ovarian cancer study. VWYL served as a consultant for Novartis Pharmaceuticals (HK) Ltd. in 2015–2016.